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Purpose of the review: Cardiovascular disease prevention trials of lipid lowering 
with statins have shown unexpected long-term benefits after the formal 
randomized treatment stopped. This finding needs further exploration since it 
raises the possibility that the trajectory of the disease can be modified. 
 
Recent findings: Extended follow up data are now available from further major 
primary prevention studies and from meta-analyses of the legacy effect of statin 
trials. New outcome studies have been proposed and launched to test the ability of 
early intervention to slow or regress atherosclerosis. 
 
Summary: Legacy effects are apparent in trials of LDL lowering in 
hypercholesterolemic and hypertensive patient cohorts. Over follow up periods of 
decades, both cardiovascular mortality and all-cause mortality are reduced in 
individuals who received 3 to 5 years of statin therapy. The phenomenon is 
observed also in studies of intensive glycemic control suggesting that it is possible 
to impact plaque development with long-term beneficial consequences. Novel 
strategies for primary prevention are being devised that include the early use of 












Current cardiovascular disease (CVD) intervention strategies are based on the 
understanding that atherosclerosis is a decades-long, silent process of 
pathological remodeling of the vessel wall that eventually manifests itself as an 
ischemic event. The age of clinical presentation, usually as acute coronary 
syndrome (ACS), peripheral artery disease, or ischemic stroke is in the sixth and 
seventh decade of life, and the medical response is to institute secondary 
prevention measures to reduce the risk of recurrent events (1,2).  By the time a 
clinical event occurs the atherosclerotic plaque has developed into a complex 
lesion that has become enriched in macrophages, and has a thin, friable cap and 
necrotic, lipid-filled core. With aggressive risk factor control stabilization and 
regression of the lesion is possible (3,4), but even when LDL cholesterol (LDLc) 
levels are reduced profoundly (almost to zero) there remains considerable 
‘residual risk’ of further events as seen in the PCSK9 (proprotein convertase 
subtilisin/kexin 9) inhibitor outcomes trials (5-7).   
 
Primary CVD prevention is undertaken to a greater or lesser degree depending on 
the health care system and the enthusiasm of practitioners.  In order to identify 
those asymptomatic individuals who most need active intervention, predictive 
tables are used such those based on SCORE in Europe (8), the Framingham risk 
model (9), or the Pooled Cohort equations as recommended by the latest USA 
guidelines (10,11). It is generally accepted that these risk tables over-emphasize 
age as a risk factor (12, 13**), and so even in the primary prevention setting 
current attention is focused on intervening late in the disease course. The 
shortcomings of these approaches (waiting for a clinical event to occur or using 
classical risk prediction methods) are now appreciated and there is an emerging 
consensus that our efforts should now be directed to altering the trajectory of 
atherogenesis much earlier in life (12-16). Available evidence, mostly from genetic 
studies (16,17,18*), indicates that even moderate LDLc lowering (and other 
avenues of risk factor control) initiated early will be highly effective in preventing 
events, and so residual risk may become a non-issue. Implementation of such a 
paradigm shift in prevention strategy will require further insight into the benefits 
and disadvantages of intervening at different stages of the disease process, and 
novel approaches to identifying those at highest risk. As set out in this review, the 
observations that are moving many to consider an early intervention approach are 
(i) an appreciation of the long-term impact of therapy as revealed in the ‘legacy 
effects’ of statin treatment and intensive glucose lowering, (ii) recognition from 
animal model studies that complete regression of lesions may be possible but only 
at the early stages of plaque development, and (iii) the impact of genetic factors on 
CVD risk and response to treatment. 
 
 
Legacy effects of cardiovascular disease intervention trials 
 
With the increasing availability of extended follow-up information from 
cardiovascular outcome trials, it has become possible to evaluate if interventions 
designed to control major causal risk factors - raised LDL cholesterol, raised blood 
pressure, elevated glucose levels in diabetes – have a long-term benefit that 
continues after study treatment has stopped. This post-trial persistence in risk 
reduction has been termed the ‘legacy’ effect or ‘carry-forward’ benefit. 
Conceptually, it is predicated on the possibility that during the randomized trial 
the drug under investigation impacted on the pathological process in a way that 
altered the natural history of the disease, with the consequence that subjects in 
the active-treatment arm going forward experience a different trajectory of risk.  
The topic has been discussed with respect to statin studies in a previous article in 
this journal (19) and in other, more recent reviews (14,15, 20). One of the latest 
reports is that of the 16-year follow up of the ASCOT (Anglo-Scandinavian Cardiac 
Outcomes Trial) (21**). The original randomized trial in hypertensive patients 
evaluated the impact of amlodipine versus atenolol, and within a Lipid-Lowering 
Arm (LLA) of atorvastatin versus placebo on major coronary events (22). The 
long-term effects of these treatments are reported for the subset of subjects 
included in the ASCOT Legacy study; these were 8580 UK-based patients for 
whom mortality data was available. While there was no significant difference in 
all-cause mortality over 16 years, there were fewer stroke deaths in the 
amlodipine treated subjects (21). In the LLA subset, atorvastatin treatment for 
about 3 years (that is, during the formal double-blind phase of the trial) was 
associated with a 15% reduced risk of death from cardiovascular causes at 16 
years (Table 1). This relative risk reduction in CVD mortality was virtually 
identical in magnitude to that seen at the end of the in-trial period (22). In 
addition, all-cause and coronary heart disease mortality showed trends to long-
term benefit in the atorvastatin treated subjects (21). These findings are in line 
with the results from the West of Scotland Coronary Prevention Study (WOSCOPS) 
in which we observed a significant 21% reduction in CVD risk (based on non-fatal 
and fatal events) over 20 years of extended follow up and a 13% decrease in total 
mortality (23). The concordance between the two trials is shown in Table 1. The 
lipid lowering arm of ALLHAT-LLT (Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial-Lipid Lowering Therapy), the third major 
primary prevention trial for which extended follow up data are available, showed 
non-significant results over the long term even for cardiovascular mortality (Table 
1). This weaker effect is usually attributed to the relatively small difference in 
LDLc between the two treatment arms in this trial (24). Of note also is the 
observation that while cardiovascular deaths were reduced in both WOSCOPS and 
ASCOT-LLA and there was a trend in ALLHAT-LLT, over the whole observation 
period stroke deaths were not impacted by statin-associated legacy effects. 
 
In an attempt to clarify further the legacy phenomenon, a meta-analysis of key 
statin studies was undertaken by Nayak et al (25*) who examined mortality rates 
in major primary and secondary prevention statin trials for which long-term 
follow-up was available. They paid particular attention to the post-trial period 
rather than total follow-up (which includes the trial itself as shown in Table 1) 
arguing that a legacy effect should be evidenced by a risk reduction once active 
treatment had stopped. A difference was noted between the five secondary 
prevention studies where no mortality benefit was found post-trial - relative risk 
(RR) 0.99 (95% confidence limits (CI) 0.94 - 1.05) - and the three primary 
prevention trials (WOSCOPS, ASCOT and ALLHAT (21,23,24)) which on aggregate 
showed a significant decrease in risk of cardiovascular mortality – RR 0.91 (CI 
0.84-0.98)- and all-cause mortality, RR 0.92 (CI 0.88-0.96). The main shortcoming 
of this analysis, as recognized by the investigators, is that event rate comparisons 
between treatment groups post-trial may be confounded by differential treatment 
effects during the formal trial. However, the concordance across studies indicates 
that early intervention in asymptomatic individuals with elevated risk factors (the 
trials were conducted in hypercholesterolemic or hypertensive cohorts) may 
provide added benefit as the treatment impacts on the atherosclerotic plaque and 
its development (see 19 for a more detailed discuss on possible mechanisms).  In 
this context, it is interesting to note that additional analysis of another primary 
prevention trial, HOPE (Heart Outcomes Prevention Evaluation)-3, showed that 
year on year during the main study there was appreciable diminution of the LDLc 
difference between the two treatment arms of the trial (due to drop-in and drop-
out) but the cumulative event curves continued to show ever greater separation 
between those on placebo and rosuvastatin (26). This was interpreted as evidence 
for a within-study legacy effect that will be investigated further with post-trial 
follow-up. 
 
Long-term follow up also provides important insights into safety of drugs where 
there is a perceived issue over tolerability or adverse events. WOSCOPS 
documented no difference in non-cardiovascular mortality or incident cancers 
over 20 years (23). The ASCOT investigators took advantage of the trial design to 
compare reported rates of adverse events on statin versus placebo during the 3-
year blinded phase and the subsequent 2-year follow-up during which monitoring 
continued. They reported that when doctor and patient were unaware of 
treatment allocation there was no difference in muscle-related side effects but 
during the open phase more patients on statin reported musculoskeletal 
symptoms (27). 
 
Statin therapy is not the only intervention in the cardiovascular field to report a 
legacy effect. Persistent, post-trial risk reductions in micro-vascular and macro-
vascular disease were found in subjects randomized to intensive glycemic control 
versus ‘usual care’ in the DCCT/EDIC study in type 1 diabetics (28*) and in the 
UKPDS trial in type 2 diabetics (29), but this has not been a universal observation 
(30). The phenomenon was explored further in a recent meta-analysis which 
reported that there was no evidence overall for a legacy effect in patients with 
type 2 diabetes who had suffered a coronary event or were at very high risk (31), 
but subjects who were newly diagnosed type 2 diabetics without established CHD 
exhibited a post-trial benefit from better glycemic control (31). Presumably again 
the stage of development of the atherosclerotic plaque was a major determinant of 
the potential for a legacy effect to occur. In terms of mechanism, the post-trial risk 
reduction may not be attributable entirely to chronically improved glucose control 
since the difference in HbA1c in UKPDS between treated groups disappeared 
within the first year of the study (29, but see also findings in 30). Other potential 
mechanisms including protein glycation, metabolic memory of target cells, and 
epigenetic changes have been explored but as yet no clear front runner has 
emerged (28, 32). In a direct comparison within a single study, the UKPDS 
investigators reported that better blood pressure control was not associated with 
a post-trial risk reduction in cardiovascular outcomes (33). However, other 
studies have suggested that a legacy effect can be seen for this risk factor as well 
(15, 20), although it may be smaller than that observed for LDL lowering (20). 
 
The appearance of legacy effects lasting decades in individuals with less advanced 
atherosclerotic disease does not mean that we should provide a relatively brief 
period of risk factor control to alter the trajectory of the pathological process and 
then relax treatment regimens. Rather, our focus should be on identifying those at 
highest risk in early adult life and instituting moderate improvements in LDLc and 
blood pressure, and in diabetics achieve better glycemic control, and by 
maintaining these interventions over the long term achieve a better than expected 
outcome. Variations on this strategy, as described below, suggest the use of more 
aggressive regimens to ‘cure’ atherosclerosis through profound LDL lowering 
(34). 
 
Novel LDL lowering intervention strategies 
If the objective of LDLc lowering is to slow, halt or reverse development of the 
atherosclerotic plaque, then the question arises as to what can be achieved at 
various stages of atherogenesis as discussed at the recent European Society of 
Cardiology roundtable (13). The earliest lesions seen in young adults take the 
form of fatty streaks (35-37) which over years progress into multicellular complex 
lesions with a thin, fragile cap which is prone to rupture, leading to an 
atherothrombotic event. Intervention to lower LDLc in people with established 
disease – usually, as noted above, aged 50-60 years and above - leads to slowed 
progression and where very low LDL levels are achieved, regression of plaque. 
The clearest example of this phenomenon in humans was observed in the GLAGOV 
(Global Assessment of Plaque Regression With a PCSK9 
Antibody as Measured By Intravascular Ultrasound) study (3) in which a PCSK9 
inhibitor was used to profoundly reduce LDLc and the majority of subjects 
exhibited reduction in lesion size. However, contrary to expectation the reduction 
in size was not accompanied by a selective decrease in lipid content or the 
necrotic core (38*). Clearly, regression of advanced lesions leaves a residual 
plaque which may be the basis for the residual risk. From animal and human 
studies, it is increasingly clear that our attention must turn to earlier lesions – the 
fatty streak- if intervention is to lead not only to plaque regression but complete 
resolution and restoration of fully functional vessel wall (12,13,34).  
 
A number of investigators have proposed intervention strategies which have the 
goal of dramatically altering cardiovascular disease trajectory as depicted in 
Figure 1. The Eliminate Coronary Artery Disease (ECAD) trial (39) was launched 
to investigate in subjects with one risk factor (smoking, truncal obesity, 
hypertension, family history of CHD, South Asian ancestry) the potential for 
moderate LDLc lowering (20mg/ day atorvastatin) to impact CVD risk in mid-life 
(age 35 to 50 years for men, 45 to 59 for women). The rationale is based on the 
observations that aboriginal populations that maintain a low LDL throughout life 
exhibit little cardiovascular disease (40), and that in Western countries those with 
inherited lower LDLc (as in PCSK9 loss-of-function variants (18, 41)) have a 
substantially decreased risk of major coronary events. The age range chosen is 
thought to be young enough so that there are few complex atherosclerotic lesions 
present but old enough to give sufficient events over a 10 -year follow-up. 
Recruitment is ongoing with an anticipated trial end in 2023 (see NCT 02245087), 
although termination is event driven. It is anticipated that in the active treatment 
arm in ECAD lesion formation will be minimized since LDLc levels are maintained 
in the range seen in CVD-free populations (‘stasis’ as depicted in Figure 1), and 
what plaque is present is unlikely to progress. The greatest challenge in such a 
long trial in asymptomatic individuals is to maintain adherence to the study 
medication. There is likely to be significant ‘drop-in’ if a non-endpoint ACS event 
occurs, or the subject decides to take up cholesterol control measures as they get 
older. ‘Drop-out’ is probably the bigger problem due to loss of interest or 
perceived side effects. In WOSCOPS we experienced 28% non-compliance to the 
study drug regimen over a 5-year period of followup (42) despite a pro-active 
program of recruit retention. Continued education and frequent communication 
with volunteers reinforcing the aims of the study will help minimize non-
compliance but the statistical power of the trial will be weakened if it is 
significant.  
 
In an alternative, more aggressive, approach, Robinson et al (43*) have outlined a 
potential clinical trial in which young to early mid-life adults with a significant 
burden of uncalcified atherosclerotic plaque are subject to profound LDLc 
lowering with target levels in the range 0.5-1.0 mmol/l (20 to 40 mg/dl - the 
‘regression’ range in Figure 1) for a short – 3-year – intervention period. The 
objective of ‘CURE-Athero’ is to ‘eradicate’ disease by regressing and resolving 
existing lesions, mainly fatty streaks. Animal studies support the concept that with 
aggressive lowering of apolipoprotein B -containing lipoproteins, lesions of this 
type can be removed and normal vessel wall regained (37, 44). The planned age 
range is 25-55 years and subjects would be recruited on the basis of the PDAY risk 
score (45) and evidence of lesions on computed tomography angiography 
imaging. The proposed end-point is change in plaque volume (43). (Note CURE-
Athero is not yet launched). If this approach were to prove successful then there 
would need to be an evaluation of the cost effectiveness of using what is an 
expensive drug in this context. The benefits would need to persist over a long 
period to balance the costs of screening and treatment. Once, the ‘eradication’ 
phase was complete then inexpensive statin therapy could be used to maintain the 
benefits over the long term, as suggested below. 
 
Variants to the design of ECAD and CURE-Athero might involve using biomarkers 
or genetics to address the issue of how best to select individuals for early 
intervention LDL lowering, and how to follow progress in regressing atheroma 
(Figure 1). Cardiac specific biomarkers such as high-sensitivity troponin- I or T 
and NT-proBNP (N-terminal proB-type natriuretic peptide) show promise in the 
general population as predictors of risk many years before an ischemic coronary 
event (46,47) and change in their circulating concentration may provide an index 
of reduction in plaque burden for those on statin therapy as suggested by the 
findings from WOSCOPS (46). Combining the approaches of the trials described 
above into a workable life-long prevention strategy might conceptually involve 
identification of a high-risk cohort of the population in early mid-life (age 30 to 50 
y) through risk factor assessment, genetic profiling, and measurement of 
biomarker levels and plaque burden. Aggressive LDL lowering (LDLc <1 mmol/l) 
can then be initiated for 3 to 5 years to resolve plaque and then a maintenance 
phase begun where moderate dose statin is used to keep LDLc below 2.6 mmol/l. 
If monitoring shows a rise in biomarkers then a further phase of aggressive 
treatment could be considered. This proposed strategy is termed ‘biomarker -
guided phased prevention’ in the figure. 
 
Use of genetics in CVD primary prevention strategies 
In addressing the issue of subject selection for intervention to alter the trajectory 
of atherosclerosis, it is worth considering the role of genetic predisposition to 
increased CVD risk. Familial hypercholesterolemia is the prime example of an 
inherited trait that leads to premature CHD (Figure 1) and identification of 
carriers of the causative gene mutations and early treatment is considered 
essential (48). It is now recognized that people with a combination of genetic 
variants that give rise to increased LDL levels are also an appropriate target for 
more aggressive intervention (49, 50). As in the case of FH it is likely that such 
individuals will have had higher LDLc levels from a young age and therefore the 
exposure – ‘LDLc x years’ – will be greater than in people with no genetic 
predisposition. Use of global genetic risk scores or LDL-specific scores may be a 
readily applicable means of selection for intervention. Further, recent studies have 
suggested that those with an increased genetic component to risk exhibit a greater 
relative risk reduction when given LDLc lowering therapy (49,51*). In a meta-
analysis combining three primary prevention studies (JUPITER [Justification for 
the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin], 
ASCOT and WOSCOPS) it was reported that, despite a similar degree of LDLc 
lowering, the relative risk reduction for subjects with a high gene score was 46% 
compared to 26% for those with a low gene score (P=0.05 for heterogeneity in 
response) (51). The agreement between trials was remarkable. Further, Natarjan 
et al (51) observed a strong association between sub-clinical atherosclerosis 
(coronary artery calcification burden) and gene score in a cohort of young adults, 
suggesting that the use of imaging as proposed in CURE-Athero (43) may also 
yield a population that responds particularly well to LDL lowering. Biomarkers 
such as C-reactive protein are strongly associated with risk of cardiovascular 
disease but their use for subject selection in the context of early intervention may 
not identify a subset of individuals who show an enhanced response to statins; in 
the JUPITER trial the relative risk reduction was the same regardless of baseline 
level of this inflammation marker (52). 
 
Conclusions 
Observations from extended follow-up of clinical trials have revealed 
unanticipated benefits from therapy in that during the post-trial period there is 
continued decrease in cardiovascular risk. The current concept is that reduction in 
causal risk factors, particularly LDLC lowering or intensive glycemic control, alters 
the trajectory of the disease by inducing changes in the nature of the plaque or 
laying down a ‘metabolic memory’ that leads to more benign conditions going 
forward. This advantageous outcome seems to be available if individuals are 
treated early in the course of the disease, and for this reason and following other 
key observations of atherosclerosis reversibility there is an emerging consensus 
that our collective attention should now focus developing better strategies in 
primary prevention aimed at identifying the subset of the population at highest 
risk and intervening to reduce dramatically or eliminate the potential for clinical 
events to occur. Implementation of this concept will be challenging but trials are 
on-gong that will demonstrate its worth.  
  
Key points 
• Primary prevention trials of statin therapy in both hypertensive (ASCOT) 
and hypercholesterolemic (WOSCOPS) patients show evidence of legacy 
effects where a risk reduction in cardiovascular disease outcomes is 
present years after the end of the formal trial.  
• LDL lowering and intensive glycemic control studies demonstrate a long-
term benefit that indicates the merits of early intervention in individuals 
who have not yet developed complex atherosclerotic lesions. 
• Novel primary prevention strategies have been proposed, and some are 
being tested to identify those most at risk before any clinical disease is 
apparent and to slow or reverse the atherogenic process. 
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Figure 1. This schematic depicts novel strategies in primary prevention focused 
on early intervention to slow, halt or reverse atherogenesis before the occurrence 
of a clinical event. Based on the prevailing LDL cholesterol concentration (LDLc), 
the ability to form atherosclerotic plaque is divided into three broad states, 
progression - where fatty streaks will eventually become complex lesions 
vulnerable to rupture, stasis - where lesion progression is unlikely, and regression 
– where any fatty streaks present will tend to shrink in size and eventually 
resolve. The decreasing horizon with age represents the cumulative exposure to 
raised LDL in LDLc x years, and is the point at which an ACS event is likely to 
occur. Inherited conditions such as familial hypercholesterolemia (FH) and PCSK9 
loss-of-function variants (R46L) provide examples of accelerated and slow 
atherogenesis (18,41,48). A potential target group for early intervention is shown. 
Individuals are identified as being at high risk on the basis of gene score, classical 
risk factors, biomarker measurement or coronary artery imaging. Intervention 
options are as in the ECAD trial (39) where subjects are given a moderate dose of 
statin to lower LDLc into the stasis range (as a target), or as in the proposed CURE-
Athero study where aggressive LDLc lowering into the regression range is used to 
resolve any early lesions present (43). The putative ‘biomarker-guided phased 
prevention’ strategy envisages episodes of aggressive and then maintenance LDLc 
lowering depending on the level of cardiac biomarkers and/or lesions on imaging. 
  
.Table 1.  Comparison of legacy effects in placebo-controlled statin 
trials in cardiovascular disease primary prevention. 
 
 
Notes: Data from references a(23), b(21), and c(24). The hazard ratios and 95th percent 
confidence limits (CI) refer to the entire length of follow up (in-trial plus post-trial events). 
The rates for ALLHAT-LLT are per 10 years. The drug used in ALLHAT and WOSCOPS was 
pravastatin, and in ASCOT was atorvastatin. In-trial LDL difference between statin versus 
placebo arms was 1.3 mmol/l for WOSCOPS, 1.2 mmol/l for ASCOT-LLA and 0.6 mmol/l 




Hazard ratio (CI) P
Cardiovascular mortality WOSCOPS (20 y)a 0.79 (0.69-0.90) 0.0004
ASCOT-LLA (16 y)b 0.85 (0.72-0.99) 0.0395
ALLHAT-LLT (8.8 y)c 0.93 (0.84-1.04) 0.19
Stroke death WOSCOPS 1.15 (0.86-1.53) 0.35
ASCOT-LLA 1.02 (0.67-1.55) 0.92
ALLHAT-LLT 1.02 (0.78-1.33) 0.89
Total mortality WOSCOPS 0.87 (0.80-0.94) 0.0007
ASCOT-LLA 0.92 (0.84-1.02) 0.091
ALLHAT-LLT 0.96 (0.89-1.03) 0.24
 
































Genetics, risk factors, imaging, biomarkers
2.0
6.0
Biomarker guided
phased prevention
